Unlike prostate, colon and breast cancers, screening for lung cancer has historically been challenging. Current methods focus primarily on smoking history, yet many individuals who develop lung cancer have no history of smoking. Now, scientists have made progress in developing a blood test that could help flag those at higher risk of developing the disease.
This breakthrough addresses a critical gap in cancer screening. Lung cancer is the leading cause of cancer deaths worldwide, partly because it is often diagnosed at advanced stages when treatment options are limited. A blood test could enable earlier detection, when the disease is more treatable. The test analyzes biomarkers in the blood that indicate the presence of lung cancer or a predisposition to it.
The development comes as new treatment modalities, such as those being developed by Calidi Biotherapeutics Inc. (NYSE American: CLDI), offer hope for patients with advanced disease. However, early detection remains key to improving survival rates. A reliable blood test could complement existing screening methods and expand the population that can be screened effectively.
Experts emphasize that while the research is promising, further validation in larger clinical trials is needed before the test can be widely adopted. The goal is to create a simple, non-invasive tool that can be used in routine check-ups, similar to blood tests for other cancers.
The potential impact is significant: if successful, this blood test could save thousands of lives each year by catching lung cancer earlier, when it is most treatable. It could also reduce the reliance on CT scans, which are currently recommended for high-risk individuals but have limitations, including high false-positive rates and radiation exposure.
As the scientific community inches closer to this goal, the implications for public health are profound. A simple blood draw could eventually become a standard part of cancer screening, transforming how lung cancer is detected and managed.
